232 related articles for article (PubMed ID: 24244902)
1. Assessing T-cell responses in anticancer immunotherapy: Dendritic cells or myeloid-derived suppressor cells?
Escors D; Liechtenstein T; Perez-Janices N; Schwarze J; Dufait I; Goyvaerts C; Lanna A; Arce F; Blanco-Luquin I; Kochan G; Guerrero-Setas D; Breckpot K
Oncoimmunology; 2013 Oct; 2(10):e26148. PubMed ID: 24244902
[TBL] [Abstract][Full Text] [Related]
2. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
3. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
De Cicco P; Ercolano G; Ianaro A
Front Immunol; 2020; 11():1680. PubMed ID: 32849585
[TBL] [Abstract][Full Text] [Related]
4. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
5. Myeloid-derived suppressor cells-a new therapeutic target to overcome resistance to cancer immunotherapy.
Chesney JA; Mitchell RA; Yaddanapudi K
J Leukoc Biol; 2017 Sep; 102(3):727-740. PubMed ID: 28546500
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor 2 ligand and interferon-γ suppress anti-tumor T cell responses by enhancing the immunosuppressive activity of monocytic myeloid-derived suppressor cells.
Shime H; Maruyama A; Yoshida S; Takeda Y; Matsumoto M; Seya T
Oncoimmunology; 2017; 7(1):e1373231. PubMed ID: 29296526
[TBL] [Abstract][Full Text] [Related]
7. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.
Groth C; Hu X; Weber R; Fleming V; Altevogt P; Utikal J; Umansky V
Br J Cancer; 2019 Jan; 120(1):16-25. PubMed ID: 30413826
[TBL] [Abstract][Full Text] [Related]
8. Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives.
Mortezaee K
Life Sci; 2021 Jul; 277():119627. PubMed ID: 34004256
[TBL] [Abstract][Full Text] [Related]
9. Modulation of the functions of myeloid-derived suppressor cells : a new strategy of hydrogen sulfide anti-cancer effects.
De Cicco P; Ercolano G; Rubino V; Terrazzano G; Ruggiero G; Cirino G; Ianaro A
Br J Pharmacol; 2020 Feb; 177(4):884-897. PubMed ID: 31392723
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
Gao X; Sui H; Zhao S; Gao X; Su Y; Qu P
Front Immunol; 2020; 11():585214. PubMed ID: 33613512
[TBL] [Abstract][Full Text] [Related]
11. Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy.
Draghiciu O; Lubbers J; Nijman HW; Daemen T
Oncoimmunology; 2015 Jan; 4(1):e954829. PubMed ID: 25949858
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine.
Ko HJ; Lee JM; Kim YJ; Kim YS; Lee KA; Kang CY
J Immunol; 2009 Feb; 182(4):1818-28. PubMed ID: 19201833
[TBL] [Abstract][Full Text] [Related]
13. Jianpi Huayu Decoction Attenuates the Immunosuppressive Status of H
Xie Y; Zhang Y; Wei X; Zhou C; Huang Y; Zhu X; Chen Y; Wen H; Huang X; Lin J; Wang Z; Ren Y; Fan B; Deng X; Tan W; Wang C
Front Pharmacol; 2020; 11():16. PubMed ID: 32140106
[TBL] [Abstract][Full Text] [Related]
14. Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells.
Yong SB; Chung JY; Song Y; Kim J; Ra S; Kim YH
Biomaterials; 2019 Oct; 219():119401. PubMed ID: 31398571
[TBL] [Abstract][Full Text] [Related]
15. Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer.
Safarzadeh E; Hashemzadeh S; Duijf PHG; Mansoori B; Khaze V; Mohammadi A; Kazemi T; Yousefi M; Asadi M; Mohammadi H; Babaie F; Baradaran B
J Cell Physiol; 2019 Apr; 234(4):3515-3525. PubMed ID: 30362521
[TBL] [Abstract][Full Text] [Related]
16. Myeloid-derived suppressor cells: The green light for myeloma immune escape.
Malek E; de Lima M; Letterio JJ; Kim BG; Finke JH; Driscoll JJ; Giralt SA
Blood Rev; 2016 Sep; 30(5):341-8. PubMed ID: 27132116
[TBL] [Abstract][Full Text] [Related]
17. Myeloid-derived suppressor cells mediate tolerance induction in autoimmune disease.
Wegner A; Verhagen J; Wraith DC
Immunology; 2017 May; 151(1):26-42. PubMed ID: 28140447
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticle Systems Modulating Myeloid-Derived Suppressor Cells for Cancer Immunotherapy.
Wilkerson A; Kim J; Huang AY; Zhang M
Curr Top Med Chem; 2017; 17(16):1843-1857. PubMed ID: 27875974
[TBL] [Abstract][Full Text] [Related]
19. Pro-inflammatory chitosan/poly(γ-glutamic acid) nanoparticles modulate human antigen-presenting cells phenotype and revert their pro-invasive capacity.
Castro F; Pinto ML; Silva AM; Pereira CL; Teixeira GQ; Gomez-Lazaro M; Santos SG; Barbosa MA; Gonçalves RM; Oliveira MJ
Acta Biomater; 2017 Nov; 63():96-109. PubMed ID: 28919508
[TBL] [Abstract][Full Text] [Related]
20. Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy.
Wang Y; Jia A; Bi Y; Wang Y; Yang Q; Cao Y; Li Y; Liu G
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32942545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
